共 84 条
[1]
Gower E(2017)Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study Lancet Gastroenterol Hepatol 2 161-176
[2]
Estes C(2014)Global epidemiology and genotype distribution of the hepatitis C virus infection J Hepatol 61 S45-S57
[3]
Blach S(2010)Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection Aliment Pharmacol Ther 32 344-355
[4]
Alazawi W(2002)Hepatocellular carcinoma: an epidemiologic view J Clin Gastroenterol 35 S72-S78
[5]
Cunningham M(2017)The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment Liver Int 37 45-53
[6]
Dearden J(2015)Medication of chronic hepatitis C: a review on sofosbuvir as a new antiviral drug ASRJETS 13 1-23
[7]
El-Serag HB(2013)Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 1878-1887
[8]
Kandeel A(2016)Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+) Hepatology 63 1430-1441
[9]
Genedy M(2015)Pharmacological properties and clinical efficacy of daclatasvir (Daklinza Nihon Yakurigaku Zasshi 145 152-162
[10]
El-Refai S(2018)) and asunaprevir (Sunvepra Aliment Pharmacol Ther 47 674-679